Skip to main content
Contact Us
Subscribe
E-Edition
73°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Recursion Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
RXRX
)
5.095
-0.195 (-3.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Recursion to Participate in Upcoming Investor Conference
Today 8:00 EDT
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
March 31, 2025
Via
The Motley Fool
Topics
Government
World Trade
Exposures
COVID-19
Political
Product Safety
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?
March 30, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Nvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI Stocks
March 30, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Why Recursion Pharmaceuticals Stock Is Sinking Today
March 10, 2025
Via
The Motley Fool
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
March 18, 2025
Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy.
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Jim Cramer: Fiserv Is 'One Of The Greatest Fintechs,' Calls This Tech Company A Meme Stock
March 10, 2025
Fiserv recently completed its acquisition of Payfare Inc. On "Mad Money Lightning Round," Jim Cramer called it "one of the greatest fintechs."
Via
Benzinga
Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?
March 08, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip
March 08, 2025
Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX.
Via
Benzinga
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today
March 07, 2025
Via
The Motley Fool
This Biotech Stock Could Be the Best Investment of the Decade
March 07, 2025
The term "game-changing" is overused for too many up-and-coming companies, but in this case, the description fits.
Via
The Motley Fool
Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?
March 06, 2025
Via
The Motley Fool
Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says
March 03, 2025
Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future revenue, according to Needham.
Via
Benzinga
Recursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The Dip
March 02, 2025
Leerink cited concerns over high cash burn and execution risks in deal-making and clinical development over the next year.
Via
Stocktwits
Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This Friday
March 01, 2025
Ark Invest made notable trades on Feb. 28, 2025. They purchased shares in ACHR, RXRX, TEM, and IRDM, while selling shares in TWST, ADYEY, ACCD, and EXAS.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
February 28, 2025
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Earnings Scheduled For February 28, 2025
February 28, 2025
Via
Benzinga
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
February 24, 2025
Company to host public (L)earnings call on February 28th at 8:30 am ET / 6:30 am MT / 1:30 pm GMT
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?
February 21, 2025
Recursion Pharmaceuticals' stock has soared due to Nvidia's continued investment, positioning the company as a leader in AI-driven drug discovery.
Via
MarketBeat
Topics
Artificial Intelligence
Regulatory Compliance
Exposures
Artificial Intelligence
Legal
Regulatory
SoundHound and Serve Robotics Are Dropping Like a Rock -- Why Nvidia Was the Catalyst
February 20, 2025
Nvidia sold their stake in some high-flying stocks recently.
Via
The Motley Fool
Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City
February 19, 2025
The Altitude Lab Fund aims to deliver strong returns to Limited Partners, accelerate the growth of Salt Lake City’s Life Science hub, and enable high potential startups support while federal funding is...
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday
February 18, 2025
Via
Benzinga
Altitude Lab Startups Raise $154M in Capital
February 18, 2025
The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones
From
Recursion Pharmaceuticals
Via
GlobeNewswire
25 Top AI Stocks That Could Boost Your Portfolio
February 18, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
SoftBank Joins Nvidia In Backing Recursion Pharma, Retail Traders Rally Behind Stock Surge
February 18, 2025
The Japanese conglomerate’s bet comes amid growing AI sector momentum, fueled in part by chipmaking giant Nvidia, which also holds over 7.7 million Recursion shares.
Via
Stocktwits
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
February 16, 2025
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
February 14, 2025
Via
Benzinga
Why Recursion Pharmaceuticals Stock Is Soaring Today
February 14, 2025
Via
The Motley Fool
Nvidia Invests in These 2 Artificial Intelligence (AI) Stocks and Sells These 3 Others
February 14, 2025
Nvidia's 13F revealed some interesting choices.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Why SoundHound AI and Serve Robotics Stock Crashed on Friday
February 14, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.